These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 16920097)
1. The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. Rotondo S; Dell'Elba G; Manarini S; Cerletti C; Evangelista V Eur J Pharmacol; 2006 Sep; 546(1-3):95-101. PubMed ID: 16920097 [TBL] [Abstract][Full Text] [Related]
2. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640 [TBL] [Abstract][Full Text] [Related]
3. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038 [TBL] [Abstract][Full Text] [Related]
4. TxA2-mediated myocardial ischemia as a consequence of an acute lung inflammatory reaction in the rabbit. Evangelista V; Dell'Elba G; Celardo A; Manarini S; Cerletti C J Thromb Haemost; 2003 Feb; 1(2):314-9. PubMed ID: 12871506 [TBL] [Abstract][Full Text] [Related]
5. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. Moreau M; Daminet S; Martel-Pelletier J; Fernandes J; Pelletier JP J Vet Pharmacol Ther; 2005 Feb; 28(1):81-6. PubMed ID: 15720519 [TBL] [Abstract][Full Text] [Related]
6. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity. Hernandez MR; Tonda R; Pedreño J; Salas E; Arderiu G; Pino M; Serradell M; Escolar G J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):859-65. PubMed ID: 17122671 [TBL] [Abstract][Full Text] [Related]
7. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Paredes Y; Massicotte F; Pelletier JP; Martel-Pelletier J; Laufer S; Lajeunesse D Arthritis Rheum; 2002 Jul; 46(7):1804-12. PubMed ID: 12124864 [TBL] [Abstract][Full Text] [Related]
8. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773 [TBL] [Abstract][Full Text] [Related]
9. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Alvaro-Gracia JM Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379 [TBL] [Abstract][Full Text] [Related]
11. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989. Spaethe SM; Hsueh W; Needleman P J Pharmacol Exp Ther; 1989 Mar; 248(3):1308-16. PubMed ID: 2539462 [TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory effect of licofelone against various inflammatory challenges. Singh VP; Patil CS; Kulkarni SK Fundam Clin Pharmacol; 2006 Feb; 20(1):65-71. PubMed ID: 16448396 [TBL] [Abstract][Full Text] [Related]
15. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. Marcouiller P; Pelletier JP; Guévremont M; Martel-Pelletier J; Ranger P; Laufer S; Reboul P J Rheumatol; 2005 Apr; 32(4):704-12. PubMed ID: 15801029 [TBL] [Abstract][Full Text] [Related]
16. Safety of anti-inflammatory treatment--new ways of thinking. Brune K Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171 [TBL] [Abstract][Full Text] [Related]
17. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Bias P; Buchner A; Klesser B; Laufer S Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890 [TBL] [Abstract][Full Text] [Related]
18. The influence of acetylshikonin, a natural naphthoquinone, on the production of leukotriene B4 and thromboxane A2 in rat neutrophils. Hsu MF; Chang LC; Huang LJ; Kuo SC; Lee HY; Lu MC; Wang JP Eur J Pharmacol; 2009 Apr; 607(1-3):234-43. PubMed ID: 19232341 [TBL] [Abstract][Full Text] [Related]